Cargando…

Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study

BACKGROUND: T1a renal cell carcinoma (RCC) is typically considered a curable disease, irrespective of the choice of local treatment modality. OBJECTIVE: To identify factors associated with the risk of local and distant recurrence, and overall survival (OS) in patients with primary nonmetastatic clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Almdalal, Tarik, Sundqvist, Pernilla, Harmenberg, Ulrika, Hellström, Mikael, Lindskog, Magnus, Lindblad, Per, Lundstam, Svan, Ljungberg, Börje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068725/
https://www.ncbi.nlm.nih.gov/pubmed/35528783
http://dx.doi.org/10.1016/j.euros.2022.03.005
_version_ 1784700279918166016
author Almdalal, Tarik
Sundqvist, Pernilla
Harmenberg, Ulrika
Hellström, Mikael
Lindskog, Magnus
Lindblad, Per
Lundstam, Svan
Ljungberg, Börje
author_facet Almdalal, Tarik
Sundqvist, Pernilla
Harmenberg, Ulrika
Hellström, Mikael
Lindskog, Magnus
Lindblad, Per
Lundstam, Svan
Ljungberg, Börje
author_sort Almdalal, Tarik
collection PubMed
description BACKGROUND: T1a renal cell carcinoma (RCC) is typically considered a curable disease, irrespective of the choice of local treatment modality. OBJECTIVE: To identify factors associated with the risk of local and distant recurrence, and overall survival (OS) in patients with primary nonmetastatic clinical T1a RCC. DESIGN, SETTING, AND PARTICIPANTS: A population-based nationwide register study of all 1935 patients with cT1a RCC, diagnosed during 2005–2012, identified through The National Swedish Kidney Cancer Register, was conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcome variables were recurrence (local or distant) and OS. Possible explanatory variables included tumor size, RCC type, T stage, surgical technique, age, and gender. Associations with disease recurrence and OS were evaluated by multivariable regression and Cox multivariate analyses, respectively. RESULTS AND LIMITATIONS: Among 1935 patients, 938 were treated with radical nephrectomy, 738 with partial nephrectomy, and 169 with ablative treatments, while 90 patients had no surgery. Seventy-eight (4%) patients were upstaged to pT3. Local or metastatic recurrences occurred in 145 (7.5%) patients, significantly more often after ablation (17.8%). The risk of recurrence was associated with tumor size, upstaging, and ablation. Larger tumor size, disease recurrence, and older age adversely affected OS, whereas partial nephrectomy and chromophobe RCC (chRCC) were associated with improved survival. Limitations include register design and a lack of comorbidity or performance status data. CONCLUSIONS: Upstaging and recurrence occurred, respectively, in 4.0% and 7.5% of patients with nonmetastatic RCCs ≤4 cm. Tumor size upstaging and ablation were associated with the risk for recurrence, while tumor size and recurrence were associated with decreased OS. Patients with chRCC and partial nephrectomy had prolonged OS in a real-world setting. PATIENT SUMMARY: We studied factors that may influence the risk of disease recurrence and overall survival, in a large nationwide patient cohort having nonmetastatic renal cell carcinoma ≤4 cm. Tumor size, tumor type, and treatment were associated with the risk of recurrence and overall death. Partial nephrectomy prolonged overall survival.
format Online
Article
Text
id pubmed-9068725
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90687252022-05-05 Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study Almdalal, Tarik Sundqvist, Pernilla Harmenberg, Ulrika Hellström, Mikael Lindskog, Magnus Lindblad, Per Lundstam, Svan Ljungberg, Börje Eur Urol Open Sci Kidney Cancer BACKGROUND: T1a renal cell carcinoma (RCC) is typically considered a curable disease, irrespective of the choice of local treatment modality. OBJECTIVE: To identify factors associated with the risk of local and distant recurrence, and overall survival (OS) in patients with primary nonmetastatic clinical T1a RCC. DESIGN, SETTING, AND PARTICIPANTS: A population-based nationwide register study of all 1935 patients with cT1a RCC, diagnosed during 2005–2012, identified through The National Swedish Kidney Cancer Register, was conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcome variables were recurrence (local or distant) and OS. Possible explanatory variables included tumor size, RCC type, T stage, surgical technique, age, and gender. Associations with disease recurrence and OS were evaluated by multivariable regression and Cox multivariate analyses, respectively. RESULTS AND LIMITATIONS: Among 1935 patients, 938 were treated with radical nephrectomy, 738 with partial nephrectomy, and 169 with ablative treatments, while 90 patients had no surgery. Seventy-eight (4%) patients were upstaged to pT3. Local or metastatic recurrences occurred in 145 (7.5%) patients, significantly more often after ablation (17.8%). The risk of recurrence was associated with tumor size, upstaging, and ablation. Larger tumor size, disease recurrence, and older age adversely affected OS, whereas partial nephrectomy and chromophobe RCC (chRCC) were associated with improved survival. Limitations include register design and a lack of comorbidity or performance status data. CONCLUSIONS: Upstaging and recurrence occurred, respectively, in 4.0% and 7.5% of patients with nonmetastatic RCCs ≤4 cm. Tumor size upstaging and ablation were associated with the risk for recurrence, while tumor size and recurrence were associated with decreased OS. Patients with chRCC and partial nephrectomy had prolonged OS in a real-world setting. PATIENT SUMMARY: We studied factors that may influence the risk of disease recurrence and overall survival, in a large nationwide patient cohort having nonmetastatic renal cell carcinoma ≤4 cm. Tumor size, tumor type, and treatment were associated with the risk of recurrence and overall death. Partial nephrectomy prolonged overall survival. Elsevier 2022-04-01 /pmc/articles/PMC9068725/ /pubmed/35528783 http://dx.doi.org/10.1016/j.euros.2022.03.005 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Kidney Cancer
Almdalal, Tarik
Sundqvist, Pernilla
Harmenberg, Ulrika
Hellström, Mikael
Lindskog, Magnus
Lindblad, Per
Lundstam, Svan
Ljungberg, Börje
Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study
title Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study
title_full Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study
title_fullStr Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study
title_full_unstemmed Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study
title_short Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study
title_sort clinical t1a renal cell carcinoma, not always a harmless disease—a national register study
topic Kidney Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068725/
https://www.ncbi.nlm.nih.gov/pubmed/35528783
http://dx.doi.org/10.1016/j.euros.2022.03.005
work_keys_str_mv AT almdalaltarik clinicalt1arenalcellcarcinomanotalwaysaharmlessdiseaseanationalregisterstudy
AT sundqvistpernilla clinicalt1arenalcellcarcinomanotalwaysaharmlessdiseaseanationalregisterstudy
AT harmenbergulrika clinicalt1arenalcellcarcinomanotalwaysaharmlessdiseaseanationalregisterstudy
AT hellstrommikael clinicalt1arenalcellcarcinomanotalwaysaharmlessdiseaseanationalregisterstudy
AT lindskogmagnus clinicalt1arenalcellcarcinomanotalwaysaharmlessdiseaseanationalregisterstudy
AT lindbladper clinicalt1arenalcellcarcinomanotalwaysaharmlessdiseaseanationalregisterstudy
AT lundstamsvan clinicalt1arenalcellcarcinomanotalwaysaharmlessdiseaseanationalregisterstudy
AT ljungbergborje clinicalt1arenalcellcarcinomanotalwaysaharmlessdiseaseanationalregisterstudy